Wet AMD Market Report 2032: Epidemiology, Market Size, Share, Therapies, Clinical Trials, Companies & Growth Analysis Report - Segmented By Therapies, Countries, by DelveInsight

(Albany, USA) DelveInsight's "Wet AMD Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Wet AMD, historical and forecasted epidemiology as well as the Wet AMD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Wet AMD market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Wet AMD market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Wet AMD treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Wet AMD market.

Request for a Free Sample Report @ https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Wet AMD Market Report are:
• According to DelveInsight, Wet AMD market size is expected to grow at a decent CAGR by 2032.
• Leading Wet AMD companies working in the market are Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Aerie Pharmaceuticals, Ashvattha Therapeutics, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Adverum Biotechnologies, TOT Biopharm, 4D Molecular Therapeutics, Abpro Corporation, Novelty Nobility, Kala Pharmaceuticals, Surrozen, Eyevensys, Ocugen, Exonate, and others.
• Key Wet AMD Therapies expected to launch in the market are OPT-302, ONS-5010, KSI-301, RGX-314, Etamsylate, GEM-103, HB002.1M, ISTH0036, Zimura, RBM-007, CU03, PF-04523655, BAT5906, ALS-L1023, AKST4290, Vorolanib (X-82), ICON-1, AIV007, BI 836880, RC 28 E, PAN 90806, CLS-AX, AS101, AXT107, UBX1325, KHK4951, OTX-TKI, AAVCAGsCD59, EYP-1901, CMAB818, AR-13503, D-4517, RG6120, 601A, ADVM-022, TAB014, 4D-150, ABP-201, NN2101, EYS609, OCU 200, EXN 169, and others.
• In August 2022, Opthea Limited announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration (wet AMD).
• In August 2022, Outlook Therapeutics, Inc. announced that it had re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).
• In August 2022, EyePoint Pharmaceuticals, Inc. announced that the first patient had been dosed in Phase 2 "Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).

Wet AMD Overview

Wet Age-related Macular Degeneration (Wet AMD) is a progressive eye disease and a leading cause of severe vision loss in people over 50. It occurs due to abnormal growth of blood vessels beneath the macula, the central part of the retina responsible for sharp vision. These new blood vessels are fragile and can leak fluid and blood, causing damage to the macula and leading to distorted or blurry central vision.

Wet AMD typically starts with dry AMD, where drusen deposits accumulate in the retina, but it can progress rapidly to the wet form. Risk factors include aging, family history, smoking, and genetic predisposition. Symptoms may include the appearance of straight lines as wavy or the presence of dark spots in the central vision.

Early diagnosis is crucial for timely intervention. Anti-VEGF (vascular endothelial growth factor) injections are the primary treatment, helping to reduce the growth of abnormal blood vessels and preserve vision. Other treatment options include photodynamic therapy and laser therapy. Although there is no cure for AMD, regular eye exams and early intervention can significantly slow down disease progression and preserve vision.

Learn more about Wet AMD treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Wet AMD Market

The Wet AMD market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Wet AMD market trends by analyzing the impact of current Wet AMD therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Wet AMD market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Wet AMD market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Wet AMD market in 7MM is expected to witness a major change in the study period 2019-2032.

Wet AMD Epidemiology

The Wet AMD epidemiology section provides insights into the historical and current Wet AMD patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Wet AMD market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Wet AMD Epidemiology @ https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Wet AMD Drugs Uptake

This section focuses on the uptake rate of the potential Wet AMD drugs recently launched in the Wet AMD market or expected to be launched in 2019-2032. The analysis covers the Wet AMD market uptake by drugs, patient uptake by therapies, and sales of each drug.

Wet AMD Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Wet AMD market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Wet AMD Pipeline Development Activities

The Wet AMD report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Wet AMD key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Wet AMD pipeline development activities @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Wet AMD Therapeutics Assessment

Major key companies are working proactively in the Wet AMD Therapeutics market to develop novel therapies which will drive the Wet AMD treatment markets in the upcoming years are Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Aerie Pharmaceuticals, Ashvattha Therapeutics, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Adverum Biotechnologies, TOT Biopharm, 4D Molecular Therapeutics, Abpro Corporation, Novelty Nobility, Kala Pharmaceuticals, Surrozen, Eyevensys, Ocugen, Exonate, and others.

Learn more about the emerging Wet AMD therapies & key companies @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Wet AMD Report Key Insights

1. Wet AMD Patient Population
2. Wet AMD Market Size and Trends
3. Key Cross Competition in the Wet AMD Market
4. Wet AMD Market Dynamics (Key Drivers and Barriers)
5. Wet AMD Market Opportunities
6. Wet AMD Therapeutic Approaches
7. Wet AMD Pipeline Analysis
8. Wet AMD Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Wet AMD Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Wet AMD Competitive Intelligence Analysis
4. Wet AMD Market Overview at a Glance
5. Wet AMD Disease Background and Overview
6. Wet AMD Patient Journey
7. Wet AMD Epidemiology and Patient Population
8. Wet AMD Treatment Algorithm, Current Treatment, and Medical Practices
9. Wet AMD Unmet Needs
10. Key Endpoints of Wet AMD Treatment
11. Wet AMD Marketed Products
12. Wet AMD Emerging Therapies
13. Wet AMD Seven Major Market Analysis
14. Attribute Analysis
15. Wet AMD Market Outlook (7 major markets)
16. Wet AMD Access and Reimbursement Overview
17. KOL Views on the Wet AMD Market
18. Wet AMD Market Drivers
19. Wet AMD Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Wet AMD Market report here @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Report:
• Central Serous Chorioretinopathy Market: https://www.delveinsight.com/report-store/central-serous-chorioretinopathy-market
• Conference Coverage Services: https://www.delveinsight.com/consulting/conference-coverage-services
• Generalized Pustular Psoriasis Market: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-gpp-market
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Menorrhalgia Market: https://www.delveinsight.com/report-store/menorrhalgia-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Thrombotic Microangiopathy Market: https://www.delveinsight.com/report-store/thrombotic-microangiopathy-tma-market
• Vascular Dementia Market: https://www.delveinsight.com/report-store/vascular-dementia-market
• Acute Heart Failure Ahf Market: https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Biliary Tract Carcinoma Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Glycogen Storage Disease Market: https://www.delveinsight.com/report-store/glycogen-storage-disease-market
• Hyperinsulinemic Hypoglycemia Market: https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-type-2-market-insight
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Refractory Chronic Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-pipeline-insight
• Ankylosing Spondylitis Bekhterevs Disease Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-market
• Balloon Catheters Market Market: https://www.delveinsight.com/report-store/balloon-catheters-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Idiopathic Membranous Nephropathy Market: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-market
• Mydriasis Market: https://www.delveinsight.com/report-store/mydriasis-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/blog/bronchopulmonary-dysplasia-treatment-market
• Chronic Gout Market: https://www.delveinsight.com/report-store/chronic-gout-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Dysthymia Market: https://www.delveinsight.com/report-store/dysthymia-market
• Spinal Stenosis Market: https://www.delveinsight.com/report-store/spinal-stenosis-devices-market
• Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market

Contact Us:

Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.